Welcome to our dedicated page for Oyster Point Pharma news (Ticker: OYST), a resource for investors and traders seeking the latest updates and insights on Oyster Point Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oyster Point Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oyster Point Pharma's position in the market.
Oyster Point Pharma has priced its underwritten public offering of 3,750,000 shares of common stock at $28.00 per share, aiming for gross proceeds of $105 million before deductions. The offering is set to close on May 19, 2020, contingent on standard closing conditions. Additionally, underwriters have a 30-day option to purchase up to 562,500 more shares at the offering price. Oyster Point Pharma specializes in developing therapies for ocular surface diseases, with its lead product candidate, OC-01, targeting dry eye disease.
Oyster Point Pharma has announced an underwritten public offering of 2,500,000 shares of its common stock, with the possibility of an additional 375,000 shares through a 30-day option for underwriters. The offering is subject to market conditions and a registration statement which has yet to become effective. This move aligns with their focus on developing therapies for ocular surface diseases, particularly their lead candidate, OC-01 nasal spray, for treating dry eye disease. The offering is managed by J.P. Morgan, Cowen, and Piper Sandler.
Oyster Point Pharma announced positive results from the Phase 3 ONSET-2 trial for its OC-01 nasal spray, targeting dry eye disease. The trial met its primary endpoint, showing significant improvement in Schirmer’s score compared to control (p0.0001). Key secondary endpoints also demonstrated symptom relief, particularly in the 1.2 mg/ml dose group. The NDA for OC-01 is planned for submission in , with a potential U.S. launch in Q4 2021 if approved. The treatment was well-tolerated, maintaining a consistent safety profile.
Oyster Point Pharma, a clinical-stage biopharmaceutical company (Nasdaq: OYST), will report its first quarter 2020 financial results on May 11, 2020, prior to market opening. Following the report, a live audio webcast and conference call will take place at 8:00 am ET. The company is developing OC-01 nasal spray, aimed at treating dry eye disease by restoring tear film homeostasis. Dry eye disease affects over 30 million Americans, highlighting a significant need for effective therapies.